Hibiscus Study: An oral investigational medication for SCD

The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.

Locations

3 sites

Age

12 to 65 years of age, inclusive

Genotypes

3

LEARN MORE
THRIVE-131 Study: A study to potentially reduce VOCs in sickle cell

The Thrive-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.

Locations

3 USA sites

1 Lebanon site

Age

12 years and older

Genotypes

All types of SCD

LEARN MORE
The MOMENTUM Study: Gene transfer for patients with sickle cell disease

The MOMENTUM study is determining if an investigational gene therapy allows the body to produce more fetal hemoglobin.

Locations

4 sites

Age

18 to 45 years old

Genotypes

3

LEARN MORE
CaRISMA Study: An alternative way to manage sickle cell disease

To identify treatments that do not rely only on opioids or other medications.

Locations

1 United States site

Age

18 years and older

Genotypes

All types of SCD

LEARN MORE